Biopharmaceutical process development: Part I, Information from the first product generation

Pharmaceutical Technology Europe

Volumn 13, Issue 6, 2001, Pages

  Foo, F ^a   Karri, S ^a   Davies, E ^a   Titchener Hooker, N ^a   Dunnill, P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DORNASE ALFA; HUMAN GROWTH HORMONE; HUMAN INSULIN; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; OKT 3; ONCOSCINT CR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; SOMATREM;

DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG DETERMINATION; DRUG INFORMATION; DRUG ISOLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SOLUBILITY; DRUG SYNTHESIS; GOOD MANUFACTURING PRACTICE; MOLECULAR CLONING; PROTEIN EXPRESSION; SHORT SURVEY; VALIDATION PROCESS;

EID: 0034960946     PISSN: 01646826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. The first biopharmaceuticals approved in the United States 1980-1994
2. Potential and efficiency in the biotechnical process
3. Protein purification: The right step at the right time
4. Novel technologies for direct extraction of proteins
5. Design, synthesis and application of a protein a mimetic